AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO025410432
Submit to EJMO
Cite this article
12
Download
46
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Marked dysregulation of mature 3p and 5p arms of miR-182 and miR-490 lacks prognostic value for 5-year survival in colorectal cancer

Arash Moradi1 ,  Seyedeh Hanieh Safavi Komamardakhi1 ,  Ramtin Mohammadi1 ,  Majid Pornour2 ,  Azar Heidarizadi1 ,  Mahmoud Hatami1 ,  Mariasanta Napolitano3* ,  Shahla Mohammad Ganji1*
Show Less
1 Department of Molecular Medicine, Medical Biotechnology Institute, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
2 Jeanie and Tony Loop Laboratory for Immuno-Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Pre-Clinical Science Building, Washington DC, United States of America
3 Department of Health Promotion, Maternal-Childhood, Internal Medicine of Excellence G.D’Alessandro, University of Palermo, Palermo, Italy
EJMO, 025410432 https://doi.org/10.36922/EJMO025410432
Received: 10 October 2025 | Revised: 5 December 2025 | Accepted: 6 January 2026 | Published online: 3 February 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Download PDF
XML
Cite
Abstract

Introduction: Colorectal cancer (CRC) is a leading cause of cancer mortality. MicroRNAs are key regulators of gene expression implicated in carcinogenesis. While miR-182 is an established oncomiR and miR-490 acts as a tumor suppressor, the prognostic significance of their mature arms (−3p/−5p) remains unclear.

Objective: This study aims to validate these mature arms in CRC and assess their association with 5-year overall survival.

Methods: We combined bioinformatics with experimental validation in 48 CRC patients. Putative targets were analyzed for their involvement in biological pathways. Expression levels were quantified in tumor and paired normal tissues using quantitative PCR. Associations with survival were evaluated using Kaplan–Meier and Cox proportional hazards models.

Results: Bioinformatics linked miR-182 targets to cell movement and miR-490 to the mitotic cell cycle. In patient tissues, miR-182-5p (fold change [FC]: 16.19) and miR-182-3p (FC: 3.38) were significantly upregulated (p<0.05). Conversely, miR-490-5p (FC: 0.26) and miR-490-3p (FC: 0.76) were significantly downregulated (p<0.05). Despite this dysregulation, multivariate Cox models showed no significant association with 5-year survival. Hazard ratios (HR) lacked significance for both miR-182-5p (HR = 0.858, 95% CI: 0.610–1.205, p=0.377) and miR-490-3p (HR = 0.665, 95% CI: 0.357–1.239, p=0.198).

Conclusion: This study validates the opposing dysregulation of mature miR-182 and miR-490 arms in CRC, reinforcing their respective oncogenic and tumor-suppressive roles. However, these profound expression changes did not translate into prognostic utility for 5-year survival in this cohort, suggesting that larger high-throughput-based studies are required to detect putative prognostic effects.

Keywords
Colorectal neoplasms
Gene expression regulation
MicroRNAs
Neoplasm
Funding
This project is financially supported by the Center for International Scientific Studies and Collaboration (CISSC) with approval number 737.
Conflict of interest
The authors declare they have no competing interests.
References
  1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi: 10.3322/caac.21834

 

  1. Anyane-Yeboa A, Bermudez H, Fredericks M, et al. The revised colorectal cancer screening guideline and screening burden at community health centers. Sci Rep. 2025;15(1):336. doi: 10.1038/s41598-024-83343-1

 

  1. Lhewa DY, Strate LL. Pros and cons of colonoscopy in management of acute lower gastrointestinal bleeding. World J Gastroenterol. 2012;18(11):1185-1190. doi: 10.3748/wjg.v18.i11.1185

 

  1. Chen B, Xia Z, Deng YN, et al. Emerging microRNA biomarkers for colorectal cancer diagnosis and prognosis. Open Biol. 2019;9(1):180212. doi: 10.1098/rsob.180212

 

  1. Keum N, Giovannucci E. Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16(12):713-732. doi: 10.1038/s41575-019-0189-8

 

  1. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356. doi: 10.1038/nm.3967

 

  1. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861-874. doi: 10.1038/nrg3074

 

  1. Ambros V. microRNAs: Tiny regulators with great potential. Cell. 2001;107(7):823-826. doi: 10.1016/s0092-8674(01)00616-x

 

  1. Shivdasani RA. MicroRNAs: Regulators of gene expression and cell differentiation. Blood. 2006;108(12):3646-3653. doi: 10.1182/blood-2006-01-030015

 

  1. Shi W, Wartmann T, Accuffi S, et al. Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer. Br J Cancer. 2024;130(1):125-134. doi: 10.1038/s41416-023-02488-4

 

  1. Gahlawat AW, Witte T, Sinn P, Schott S. Circulating cf-miRNA as a more appropriate surrogate liquid biopsy marker than cfDNA for ovarian cancer. Sci Rep. 2023;13(1):5503. doi: 10.1038/s41598-023-32243-x

 

  1. Rao BH, Bouskova V, Heczko L, et al. Comprehensive transcriptome and miRNome profiling in metachronous colorectal liver metastasis: Insight into the prognostic and molecular subtypes. Lab Invest. 2025;106:104274. doi: 10.1016/j.labinv.2025.104274

 

  1. Guo L, Yu J, Yu H, et al. Evolutionary and expression analysis of miR-#-5p and miR-#-3p at the miRNAs/isomiRs levels. Biomed Res Int. 2015;2015:168358. doi: 10.1155/2015/168358

 

  1. Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016;1(1):15004. doi: 10.1038/sigtrans.2015.4

 

  1. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144(5):646-674. doi: 10.1016/j.cell.2011.02.013

 

  1. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006;94(6):776-780. doi: 10.1038/sj.bjc.6603023

 

  1. He X, Dong Y, Wu CW, et al. MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol Med. 2013;18(1):1491-1498. doi: 10.2119/molmed.2012.00304

 

  1. Wu CW, Evans JM, Huang S, et al. A comprehensive approach to sequence-oriented IsomiR annotation (CASMIR): Demonstration with IsomiR profiling in colorectal neoplasia. BMC Genomics. 2018;19(1):401. doi: 10.1186/s12864-018-4794-7

 

  1. Franco S, Pluvinet R, Sanchez-Herrero JF, Sumoy L, Martinez MA. Rapid and accurate quantification of isomiRs by RT-qPCR. Sci Rep. 2022;12(1):17220. doi: 10.1038/s41598-022-22298-7

 

  1. Kramer MF. Stem-loop RT-qPCR for miRNAs. Curr Protoc Mol Biol. 2011;Chapter 15:Unit 15 10. doi: 10.1002/0471142727.mb1510s95

 

  1. Chang L, Zhou G, Soufan O, Xia J. miRNet 2.0: Network-based visual analytics for miRNA functional analysis and systems biology. Nucleic Acids Res. 2020;48(W1):W244-W251. doi: 10.1093/nar/gkaa467

 

  1. Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556-W560. doi: 10.1093/nar/gkz430

 

  1. Ge SX, Jung D, Yao R. ShinyGO: A graphical gene-set enrichment tool for animals and plants. Bioinformatics. 2020;36(8):2628-2629. doi: 10.1093/bioinformatics/btz931

 

  1. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-188. doi: 10.1111/his.13975

 

  1. Soheilifar MH, Vaseghi H, Seif F, et al. Concomitant overexpression of mir-182-5p and mir-182-3p raises the possibility of IL-17-producing Treg formation in breast cancer by targeting CD3d, ITK, FOXO1, and NFATs: A meta-analysis and experimental study. Cancer Sci. 2021;112(2):589-603. doi: 10.1111/cas.14764

 

  1. Davidson-Pilon C. Lifelines: Survival analysis in Python. J Open Source Softw. 2019;4(40):1317. doi: 10.21105/joss.01317

 

  1. Sameti P, Tohidast M, Amini M, Bahojb Mahdavi SZ, Najafi S, Mokhtarzadeh A. The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target. Cancer Cell Int. 2023;23(1):134. doi: 10.1186/s12935-023-02972-0

 

  1. Popa ML, Ichim C, Anderco P, Todor SB, Pop- Lodromanean D. MicroRNAs in the diagnosis of digestive diseases: A comprehensive review. J Clin Med. 2025;14(6):2054. doi: 10.3390/jcm14062054

 

  1. Li X, Zhang X, Zhang Q, Lin R. miR-182 contributes to cell proliferation, invasion and tumor growth in colorectal cancer by targeting DAB2IP. Int J Biochem Cell Biol. 2019;111:27-36. doi: 10.1016/j.biocel.2019.04.002

 

  1. Zehtabi M, Ghaedrahmati F, Dari MAG, et al. Emerging biologic and clinical implications of miR-182-5p in gynecologic cancers. Clin Transl Oncol. 2025;27(6): 2367-2382. doi: 10.1007/s12094-024-03822-9

 

  1. Kokaine L, Daneberga Z, Satcs M, et al. The prognostic role of microRNAs 142-5p, 182-3p, and 99a-3p in locally advanced rectal cancer patients. Anticancer Res. 2025;45(9):3895-3912. doi: 10.21873/anticanres.17748

 

  1. Kandil NS, Kandil LS, Mohamed R, et al. The role of miRNA-182 and FOXO3 expression in breast cancer. Asian Pac J Cancer Prev. 2022;23(10):3361-3370. doi: 10.31557/APJCP.2022.23.10.3361

 

  1. Vinchure OS, Kulshreshtha R. miR-490: A potential biomarker and therapeutic target in cancer and other diseases. J Cell Physiol. 2021;236(5):3178-3193. doi: 10.1002/jcp.30119

 

  1. Liu X, He B, Xu T, et al. MiR-490-3p functions as a tumor suppressor by inhibiting oncogene VDAC1 expression in colorectal cancer. J Cancer. 2018;9(7):1218-1230. doi: 10.7150/jca.23662

 

  1. Wang B, Yin M, Cheng C, et al. Decreased expression of miR4903p in colorectal cancer predicts poor prognosis and promotes cell proliferation and invasion by targeting RAB14. Int J Oncol. 2018;53(3):1247-1256. doi: 10.3892/ijo.2018.4444

 

  1. Zhu X, Lin SQ, Xie J, et al. Biomarkers of lymph node metastasis in colorectal cancer: Update. Front Oncol. 2024;14:1409627. doi: 10.3389/fonc.2024.1409627

 

  1. Wang F, Zhong S, Zhang H, et al. Prognostic value of MicroRNA-182 in cancers: A meta-analysis. Dis Markers. 2015;2015:482146. doi: 10.1155/2015/482146

 

  1. Mayeux R. Biomarkers: Potential uses and limitations. NeuroRx. 2004;1(2):182-188. doi: 10.1602/neurorx.1.2.182
Next article in this issue
Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept